AUTHORS
Toby A. Eyre, MBChB, DipMedEd, MRCP, MD, Nicolas Martinez-Calle, MD2, Shankaranarayana Paneesha, MD3, Mohsen Norouzi4, David Tucker, MBBS, BSc, DPhil, FRCPath5, Harriet Sarah Walter, MBChB PhD6, Alison Boden7, Mari Kilner8, Neil Phillips9, Piers E M Patten, MB ChB PhD10, Nimish Shah, MD, MRCP, FRCPath11, Meghna Ruparelia12, Sharon Oddy13, Sarah Goodwin14, Francesco Forconi, MD, PhD, DM, FRCPath15, Helen Wardle16, Tobore Gbemre17, Chris Gregory18, Lucy Cook, MD, PhD, MBBS, BSc, MB19, David Allsup20, Anna Morris21, Christopher Knechtli, PhD, FRCP, FRCPath22, Jenni Davies23, Helen Marr24, Claire Hutchinson25, Stella Williams26, Beena Pushkaran27, Joe Hickey28, Charlotte Richardson, BSc29, Sukhjit Hunjan30, Betina T Blak31, Renata Walewska32
AFFILIATIONS
1 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
2 Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
3 University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
4 James Cook University Hospital, Middlesbrough, United Kingdom
5 Royal Cornwall Hospital NHS Trust, Treliske, United Kingdom
6 University Hospitals Leicester NHS Trust, Leicester, United Kingdom
7 United Lincolnshire Hospitals NHS Trust, Lincoln, United Kingdom
8 North Tyneside General Hospital, North Shields, United Kingdom
9 University Hospitals of North Midlands Trust, Department of Haematology, Stoke on Trent, UK, Stoke-on-Trent, United Kingdom
10 King's College London, London, United Kingdom, King’s College Hospital, London, United Kingdom
11 Norfolk and Norwich University Hospitals NHS Foundation Trust, Norfolk, United Kingdom
12 Royal Derby Hospital, Derby, United Kingdom
13 Mid Yorkshire Teaching Hospital NHS Trust, Wakefield, United Kingdom
14 East Sussex Healthcare NHS Trust, East Sussex, United Kingdom
15 Southampton General Hospital, Southampton, United Kingdom
16 University Hospital of North Tees, Stockton-on-Tees, United Kingdom
17 Doncaster and Bassetlaw Teaching Hospitals NHS Trust, Doncaster, United Kingdom
18 Royal Albert Edward Infirmary, Wigan, United Kingdom
19 Imperial College Healthcare NHS Trust, London, United Kingdom
20 University of Hull, Hull, United Kingdom
21 Dorset County Hospital NHS Trust, Dorchester, United Kingdom
22 Royal United Hospital NHS Foundation Trust, Bath, United Kingdom
23 University Hospital of Wales, Cardiff, United Kingdom
24 Freeman Hospital, Newcastle, United Kingdom
25 University Hospitals Plymouth NHS Trust and The University of Plymouth, Plymouth, United Kingdom
26 Clatterbridge Cancer Centre, Liverpool, United Kingdom
27 Stoke Mandeville Hospital, Aylesbury, United Kingdom
28 OPEN Health, London, United Kingdom
29 AstraZeneca, London, United Kingdom
30 AstraZeneca, London, United Kingdom
31 AstraZeneca, London, United Kingdom
32 University Hospitals Dorset, Bournemouth, United Kingdom
ABSTRACT
Introduction
Clinical trials have demonstrated that acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, is safe and effective for the treatment of patients (pts) with chronic lymphocytic leukemia (CLL). However, long-term real-world evidence focused on its broader clinical effectiveness and associated healthcare use remains limited. This study generated real-world data on clinical outcomes and healthcare use in UK pts with CLL who were treated with first-line acalabrutinib monotherapy.
Methods
A multi-center retrospective chart review study was conducted including adults aged ≥18 years (y) with previously untreated CLL who received acalabrutinib monotherapy as part of a UK-wide early access program (NCT05557695). These pts received their first dose of acalabrutinib between 01/04/2020–01/04/2021 and were followed for up to 60 months from acalabrutinib initiation (index). Data collected were from medical records and included real-world progression free survival (rwPFS), real-world overall survival (rwOS), real-world response rate (rwRR), real-world treatment continuation, healthcare resource use, treatment patterns, and prespecified adverse events (AEs) that caused treatment discontinuation/interruption or hospitalization.
Results
Data from 287 CLL pts (55% male, n=159) were collected from 29 sites in England (98%, n=282) and Wales (2%, n=5) with a median age of 74.0 y (interquartile range [IQR]: 68.6–79.3) at acalabrutinib initiation. Median time from CLL diagnosis to acalabrutinib initiation was 3.1 y (IQR: 1.2–5.7) and pts were followed for a median of 60.0 months (IQR: 56.7–60.0). Hypertension (44%, n=127) and type 2 diabetes (18%, n=51) were the most common baseline comorbidities.
RwPFS at 5 y was 71.4% (95% confidence interval [CI] 66.3–76.9). Numerically higher rwPFS was observed in pts aged <75 y compared with those ≥75 y (76.1% [69.7–83.1], n=157 vs. 65.7% [58.0–74.5], n=130) and in those with a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 versus ≥1 (86.7% [79.0–95.2], n=68 vs. 65.3% [56.7–75.1], n=104). Otherwise, PFS was consistent across subgroups, including in pts with bulky disease and/or IgHV-unmutated CLL. The rwRR (95% CI) was 85.5% (81.2–89.8) at 5 y.
During follow-up, 64 pts died, of which 6 were CLL related (n=5 progressive CLL, n=1 Richter transformation); infection was the most common cause of non-CLL related death (n=20/52). RwOS at 5 y was 77.4% (72.7–82.4) and it was numerically higher in pts with ECOG 0 compared with ≥1 (94.1% [88.6–99.9], n=68 vs. 71.1% [62.9–80.4], n=104) and in those <75 y versus ≥75 y (85.2% [79.8–91.0], n=157 vs. 68.0% [60.4–76.6], n=130).
At 5 y of follow‑up, 63% of pts (n=182) remained on treatment. The most common reasons for discontinuation were AEs (40%, n=42/105), death (18%, n=19/105), and disease progression (13%, n=14/105).
Most pts (98%) initiated acalabrutinib at 100 mg twice daily. Dose reduction occurred in 17% of pts, typically within a median of 3.7 months (IQR: 1.6–20.8) post-index. Treatment interruptions were reported in 43% of pts—usually a single event occurring at a median of 14 months (IQR: 2.8–25.5). Over half of interruptions (56%) were due to AEs, most commonly upper respiratory infections (n=16), cardiovascular events (n=8), pneumonia (n=8), and neutropenia (n=7).
During follow-up, 21% (n=59) of pts were hospitalized in relation to CLL, primarily due to infections (pts n=33, event n=51) and CLL symptoms (pts n=7, event n=9), with a median hospital stay of 6.5 days (IQR 3.0–11.0, event n=82). Most pts had ≤1 hospitalization per y (14%), and higher rates were uncommon (>1–≤2: 2%; >2–≤3: 1%; >3: 3%). Overall, pts experienced a median of zero (IQR 0–0) hospitalizations per y (mean: 0.4, standard deviation: 2.2).
Out of 287 pts, 116 (40%) experienced ≥1 prespecified AE of which the most frequent were upper respiratory tract infection (n=25, 9%), cardiovascular events (n=17, 6%), pneumonia (n=14, 5%), fatigue (n=14, 5%), anemia (n=13, 5%), rash (n=13, 5%), and neutropenia (n=13, 5%).
Conclusions
Survival outcomes observed (rwPFS: 71.4%, rwOS: 77.4%) are consistent with those reported in the ELEVATE‑TN trial (NCT02475681, 5 y PFS: 72%, 5 y OS: 84%). This study provides valuable long‑term real‑world evidence on first-line acalabrutinib in CLL for efficacy, safety, dose interruptions and health care resource burden complementing published trial data. Causes of death are primarily not directly related to progressive CLL.
DISCLOSURES
Toby A. Eyre, MBChB, DipMedEd, MRCP, MD: Galapagos - Honoraria; Beigene - Honoraria; Loxo Oncology - Honoraria; KITE - Honoraria; BMS - Honoraria; Autolus - Honoraria; Nurix - Honoraria; Janssen - Honoraria; Incyte - Honoraria; AbbVie - Honoraria; Gilead - Honoraria; Roche - Honoraria; AstraZeneca - Honoraria; Lilly - Honoraria; Gilead - Research Funding; AstraZeneca - Research Funding; Beigene - Research Funding; Beigene - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); Loxo Oncology - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Galapagos - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); KITE - Consultancy (Includes expert testimony)